Australia markets closed

Aditxt, Inc. (ADTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1708+0.0005 (+0.29%)
At close: 04:00PM EDT
0.1730 +0.00 (+1.29%)
Pre-market: 07:01AM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Amro Albanna, CEO of Aditxt, Inc.

    LOS ANGELES, Aug. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operatin

  • Business Wire

    Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials

    RICHMOND, Va., July 08, 2022--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune™, has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseas

  • PR Newswire

    Premier Medical Laboratory Services Now Offering AditxtScore™ Personalized Immune Test for COVID-19

    Premier Medical Laboratory Services (PMLS), a nation leading advanced medical diagnostics lab, adds AditxtScore™ to its menu of testing services. Providing more clarity regarding a patient's individual immunity profile, AditxtScore™ allows patients to know their level of protection that an immune response to the virus or vaccination has provided them. Now that a large segment of the population has either undergone vaccination or experienced a symptomatic or asymptomatic infection with SARS-CoV-2